<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434472</url>
  </required_header>
  <id_info>
    <org_study_id>2398.00</org_study_id>
    <secondary_id>NCI-2011-01189</secondary_id>
    <secondary_id>2398.00</secondary_id>
    <secondary_id>P01CA044991</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01434472</nct_id>
  </id_info>
  <brief_title>High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma</brief_title>
  <official_title>A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well high-dose yttrium-90
      (Y-90)-ibritumomab tiuxetan (anti-cluster of differentiation [CD]20) followed by fludarabine
      phosphate, low-dose total body irradiation (TBI), and donor peripheral blood stem cell
      transplant (PBSCT) work in treating patients with aggressive B-cell lymphoma that has
      returned after a period of improvement (relapsed) or has not responded to previous treatment
      (refractory). Radiolabeled monoclonal antibodies, such as Y-90-ibritumomab tiuxetan, can find
      cancer cells and carry cancer-killing substances to them with less effect on normal cells.
      Giving chemotherapy, such as fludarabine phosphate, and TBI before a donor PBSCT helps stop
      the growth of cancer cells. It may also stop the patient's immune system from rejecting the
      donor's stem cells. However, high-dose radiolabeled antibodies also destroy healthy blood
      cells in the patient's body. When healthy stem cells from a donor are infused into the
      patient (stem cell transplant), they may help the patient's body replace these blood cells.
      Giving high-dose Y-90-ibritumomab tiuxetan followed by fludarabine phosphate, TBI, and donor
      PBSCT may be an effective treatment for patients with B-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the safety and efficacy of 1.5 mCi/kg (max 120 mCi) 90Y-Ibritumomab tiuxetan
      (yttrium Y 90 ibritumomab tiuxetan) (anti-CD20) combined with fludarabine (fludarabine
      phosphate) (30 mg/m^2 x 3) and 2 gray (Gy) total body irradiation followed by human leukocyte
      antigens (HLA) matched allogeneic hematopoietic transplantation for patients with relapsed or
      refractory aggressive B-cell lymphoma.

      OUTLINE:

      Beginning 24-48 hours prior to therapy infusion, patients receive rituximab intravenously
      (IV) over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab
      tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine
      phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients
      also receive cyclosporine orally (PO) twice daily (BID) on days -3 to 56 with taper to day
      180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate
      mofetil PO BID on days 0-27 (related donor) or PO thrice daily (TID) on days 0-40 with taper
      to day 96 (unrelated donor).

      After completion of study treatment and assessments through ~day 100 following transplant,
      patients are followed up at 1, 3, 6, and 12 months and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2011</start_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Based on a one-sample chi-square test with one-sided significance level of five percent. This study will be deemed successful if the 1 year progression-free survival of this highest-risk group of patients is 54% or greater.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment and hematopoietic toxicity</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Toxicity graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>Day 100</time_frame>
    <description>Defined as death in the absence of progressive lymphoma that can be possibly, probably, or definitely attributed to the radioimmunotherapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Post-Transplant Lymphoproliferative Disorder</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Burkitt Lymphoma</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Burkitt Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Indium In-111 Ibritumomab Tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>IDEC In2B8</other_name>
    <other_name>IDEC-In2B8</other_name>
    <other_name>In 111 Ibritumomab Tiuxetan</other_name>
    <other_name>In 111 Zevalin</other_name>
    <other_name>indium In 111 ibritumomab tiuxetan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV prior to yttrium Y 90 ibritumomab tiuxetan</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y-90 Ibritumomab Tiuxetan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)</arm_group_label>
    <other_name>IDEC-Y2B8</other_name>
    <other_name>IDEC-Y2B8 monoclonal antibody</other_name>
    <other_name>Y 90 Ibritumomab Tiuxetan</other_name>
    <other_name>Y 90 Zevalin</other_name>
    <other_name>Yttrium Y 90 Ibritumomab Tiuxetan</other_name>
    <other_name>yttrium Y90 ibritumomab tiuxetan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of aggressive B-cell lymphoma
             (diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], etc.) expressing the
             CD20 antigen and have failed at least one prior standard systemic therapy

          -  Patients must have relapsed after high-dose therapy and autologous transplantation or
             be ineligible for high-dose therapy and autologous transplantation; patients that have
             failed autologous transplantation are those with persistent disease &gt; 30 days after
             transplant; those ineligible for autologous transplant include those with
             chemoresistant disease (i.e., patients who have not achieved a partial response or
             better with their most recent chemotherapy regimen), are expected to have a poor
             outcome from autologous transplant (e.g., DLBCL relapsing within one year of
             rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate,
             prednisone [R-CHOP]-like chemotherapy, double hit lymphoma, v-myc myelocytomatosis
             viral oncogene homolog (avian) positive [MYC+] lymphoma, persistent positron emission
             tomography [PET] positivity after chemotherapy), are unable to collect sufficient or
             tumor-free autologous stem cells per Seattle Cancer Care Alliance (SCCA) standard
             practice, are unable to tolerate the high-dose autologous conditioning regimens, or
             who refuse a high-dose autologous transplant regimen

          -  Creatinine (Cr) &lt; 2.0

          -  Bilirubin &lt; 1.5 mg/dL with the exception of patients thought to have Gilbert's
             syndrome, who may have a total bilirubin above 1.5 mg/dL

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &lt; 3 x upper limit of
             normal (ULN)

          -  Patients must have an expected survival without treatment of &gt; 60 days and must be
             free of major infection including human immunodeficiency virus (HIV)

          -  Patients must have an HLA-identical related or HLA-matched unrelated donor

        Exclusion Criteria:

          -  Receipt of systemic anti-lymphoma therapy withinthe following intervals prior to the
             therapeutic 90Y-ibritumomab tiuxetan dose:

               -  &lt; 30 days for intravenously-administered cytotoxic chemotherapy and/or monoclonal
                  antibodies

               -  &lt; 5 half-lives for all other anti-cancer agents (e.g., targeted therapies,
                  corticosteroids, immunomodulatory agents, etc.)

          -  Inability to understand or give an informed consent

          -  Active central nervous system lymphoma

          -  Pregnancy

          -  Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following treatment

          -  Southwest Oncology Group (SWOG)/Eastern Cooperative Oncology Group (ECOG) performance
             score &gt;= 2

          -  High-dose chemotherapy or external beam radiation therapy to lung, liver, or kidneys &gt;
             20 Gy within the previous 100 days prior to therapeutic 90Y-ibritumomab tiuxetan dose

          -  Medical condition that would contraindicate allogeneic transplantation as per standard
             practice guidelines (e.g., impaired cardiopulmonary function, hepatitis, etc)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Gopal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay K. Gopal</last_name>
      <phone>206-288-2037</phone>
      <email>agopal@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Ajay K. Gopal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2011</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

